MoFo BioMeter - Vol. 3, Issue 1, March 2014 - Q4 and FY 2013 BioMeter Shows Rebound in Value for Late Stage Products and Strong Results Across All Stages of Development Regional Analysis Shows SF Leads But Others Are Close (and It’s Not Who You Think)

more+
less-

The full-year 2013 BioMeter analysis shows across-the-board increases in BioMeter value, with an average of $33.9 million for all transactions, up from approximately $21.2 million in 2012. Increases occurred for each stage of development, with the BioMeter for preclinical/discovery transactions averaging approximately $21.8 million in 2013, compared to approximately $10 million in 2012; the BioMeter value for Phase 1 products averaging approximately $40 million in 2013 compared to approximately $10 million in 2012; the BioMeter value for Phase 2 products increasing to approximately $47.4 million in 2013 from approximately $37.1 million in 2012; the BioMeter value for Phase 3 products increasing to approximately $46.2 million in 2013 from approximately $24.6 million in 2012; and the BioMeter value for approved products increasing to approximately $50.6 million in 2013 from approximately $27 million in 2012.

This data shows strength for sellers/licensors across all stages of the drug development spectrum. Indeed, the only reason that the overall average BioMeter did not jump more compared to 2012 is because of the mix of transactions. In 2013, preclinical/discovery transactions accounted for approximately 48% of transactions reporting up-front payments and reporting stage of development, compared to approximately 38% of transactions in 2012.

Please see full issue below for more information.

LOADING PDF: If there are any problems, click here to download the file.

Written by:

more+
less-

Morrison & Foerster LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×